Ali A El Solh1, Goda Choi, Marcus J Schultz, Lilibeth A Pineda, Corey Mankowski. 1. Western New York Respiratory Research Center, Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY 14215, USA. solh@buffalo.edu
Abstract
OBJECTIVE: To determine pathogen-specific kinetic changes in the alveolar procoagulant (PC) activity, tissue factor (TF), and tissue factor pathway inhibitor (TFPI) expression during the course of ventilator-associated pneumonia (VAP) and to assess the relationship between clinical resolution, intra-alveolar bacterial eradication, and restoration of hemostatic balance. DESIGN: Prospective, multiple-center study in a cohort of VAP patients. SETTING: Two university-affiliated intensive care units. PATIENTS: Thirty-five patients with microbiologically documented VAP who received adequate antimicrobial coverage and 13 controls. INTERVENTIONS: Nonbronchoscopic bronchoalveolar lavage was performed at the onset of VAP and on days 4 and 8 after initiation of antibiotic therapy. Samples were assayed for PC, TF, TFPI, and thrombin-antithrombin complex (TATc). The corresponding Clinical Pulmonary Infection Score (CPIS) was collected simultaneously. MEASUREMENTS AND MAIN RESULTS: Isolated pathogens included Pseudomonas aeruginosa (n=13), methicillin-resistant Staphylococcus aureus (MRSA) (n=8), methicillin-sensitive S. aureus (MSSA) (n=7), and Escherichia coli (n=7). Although PC activity and TF were increased among the various pathogens at the onset of VAP, the levels of those with P. aeruginosa remained elevated at the end of treatment compared with controls and other etiological agents. TFPI levels were elevated for the duration of the study for all pathogens. A universal increase in TATc was noted at the onset of VAP, but the difference among the group of pathogens was significant at days 4 and 8 posttherapy. Despite the persisting hemostatic imbalance and incomplete intra-alveolar eradication of P. aeruginosa at end of therapy, the CPIS fell comparably at each time point irrespective of the etiological agents. CONCLUSIONS: Alveolar activation of the TF-dependent pathway may be species-specific in VAP and may not be adequately balanced by TFPI. The disparity between clinical response and eradication of P. aeruginosa from the intra-alveolar space suggests the need for biological markers to guide response to therapy.
OBJECTIVE: To determine pathogen-specific kinetic changes in the alveolar procoagulant (PC) activity, tissue factor (TF), and tissue factor pathway inhibitor (TFPI) expression during the course of ventilator-associated pneumonia (VAP) and to assess the relationship between clinical resolution, intra-alveolar bacterial eradication, and restoration of hemostatic balance. DESIGN: Prospective, multiple-center study in a cohort of VAP patients. SETTING: Two university-affiliated intensive care units. PATIENTS: Thirty-five patients with microbiologically documented VAP who received adequate antimicrobial coverage and 13 controls. INTERVENTIONS: Nonbronchoscopic bronchoalveolar lavage was performed at the onset of VAP and on days 4 and 8 after initiation of antibiotic therapy. Samples were assayed for PC, TF, TFPI, and thrombin-antithrombin complex (TATc). The corresponding Clinical Pulmonary Infection Score (CPIS) was collected simultaneously. MEASUREMENTS AND MAIN RESULTS: Isolated pathogens included Pseudomonas aeruginosa (n=13), methicillin-resistant Staphylococcus aureus (MRSA) (n=8), methicillin-sensitive S. aureus (MSSA) (n=7), and Escherichia coli (n=7). Although PC activity and TF were increased among the various pathogens at the onset of VAP, the levels of those with P. aeruginosa remained elevated at the end of treatment compared with controls and other etiological agents. TFPI levels were elevated for the duration of the study for all pathogens. A universal increase in TATc was noted at the onset of VAP, but the difference among the group of pathogens was significant at days 4 and 8 posttherapy. Despite the persisting hemostatic imbalance and incomplete intra-alveolar eradication of P. aeruginosa at end of therapy, the CPIS fell comparably at each time point irrespective of the etiological agents. CONCLUSIONS: Alveolar activation of the TF-dependent pathway may be species-specific in VAP and may not be adequately balanced by TFPI. The disparity between clinical response and eradication of P. aeruginosa from the intra-alveolar space suggests the need for biological markers to guide response to therapy.
Authors: Florry E van den Boogaard; Cornelis van 't Veer; Joris J T H Roelofs; Joost C M Meijers; Marcus J Schultz; George J Broze; Tom van der Poll Journal: Thromb Haemost Date: 2015-04-02 Impact factor: 5.249
Authors: Daniel Aiello; John D Williams; Helena Majgier-Baranowska; Ishan Patel; Norton P Peet; Jin Huang; Stephen Lory; Terry L Bowlin; Donald T Moir Journal: Antimicrob Agents Chemother Date: 2010-02-22 Impact factor: 5.191
Authors: Kristie L Hilliard; Eri Allen; Katrina E Traber; Kazuko Yamamoto; Nicole M Stauffer; Gregory A Wasserman; Matthew R Jones; Joseph P Mizgerd; Lee J Quinton Journal: Am J Respir Cell Mol Biol Date: 2015-09 Impact factor: 6.914
Authors: Ali A El-Solh; Daniel Amsterdam; Ahmad Alhajhusain; Morohonfolu E Akinnusi; Ranime G Saliba; Susan V Lynch; Jeanine P Wiener-Kronish Journal: J Infect Date: 2009-05-23 Impact factor: 6.072
Authors: Ali A El Solh; Morohunfolu E Akinnusi; Jeanine P Wiener-Kronish; Susan V Lynch; Lilibeth A Pineda; Kristie Szarpa Journal: Am J Respir Crit Care Med Date: 2008-05-08 Impact factor: 21.405
Authors: Lynnae D Hyatt; Gregory A Wasserman; Yoon J Rah; Kori Y Matsuura; Fadie T Coleman; Kristie L Hilliard; Zachary Ash Pepper-Cunningham; Michael Ieong; Deborah J Stumpo; Perry J Blackshear; Lee J Quinton; Joseph P Mizgerd; Matthew R Jones Journal: PLoS One Date: 2014-10-09 Impact factor: 3.240